Articles by Nick Paul Taylor
When Gilead Sciences' ($GLD) Truvada was approved as an HIV preventative last year, it was hailed as a historic event. It was the first time an HIV drug had been approved to stave off HIV infection, rather than treat those who had already contracted the virus.
The measles outbreak in Wales has now infected almost 900 people--with 121 cases coming in the past week--and may have caused its first death.
The spread of H7N9 in China is a reminder of why the Department of Health and Human Services (HHS) gave Novartis $487 million to build its cell culture vaccine production plant. If H7N9 reaches the U.S., the country will be better prepared because of the investment.
While Chinese officials faced some criticism for a perceived delay in announcing last month's H7N9 outbreak, positive sentiments from global health officials have far outweighed the negative comments, in sharp contrast to the SARS outbreak a decade ago.
BIO and the International Federation of Pharmaceutical Manufacturers & Associations warn that more funding is needed to maintain current immunization rates while adding new vaccines to programs.
Alleged links between vaccines and the nerve-degenerative disorder Guillain-Barré are among vaccine safety fears. A new study shows that any link between them is not strong enough to outweigh the benefits of vaccines.
India's government wants the country to become the world's preeminent low-cost vaccine supplier, but it will first have to overcome problems of its own making.
A U.S. study has shown the importance of people's social networks in vaccination choices, with the presence of anti-immunization friends correlating with parents deciding against giving shots.
The rise of vaccine manufacturers in emerging markets, particularly India, has helped depress the cost of immunization in recent years. Indian suppliers have rolled out vaccines at significant discounts and Western manufacturers have followed suit, slashing prices in poorer countries.
The arms race analogy for vaccines is rarely more apt than during a pandemic flu outbreak. Last week the U.S. touted a new, more streamlined approach to vaccine development. This week the virus raised the stakes with a surge of new cases that suggest it is adapting to human hosts.